Literature DB >> 21731174

Dimension reduced kernel estimation for distribution function with incomplete data.

Zonghui Hu1, Dean A Follmann, Jing Qin.   

Abstract

This work focuses on the estimation of distribution functions with incomplete data, where the variable of interest Y has ignorable missingness but the covariate X is always observed. When X is high dimensional, parametric approaches to incorporate X - information is encumbered by the risk of model misspecification and nonparametric approaches by the curse of dimensionality. We propose a semiparametric approach, which is developed under a nonparametric kernel regression framework, but with a parametric working index to condense the high dimensional X - information for reduced dimension. This kernel dimension reduction estimator has double robustness to model misspecification and is most efficient if the working index adequately conveys the X - information about the distribution of Y. Numerical studies indicate better performance of the semiparametric estimator over its parametric and nonparametric counterparts. We apply the kernel dimension reduction estimation to an HIV study for the effect of antiretroviral therapy on HIV virologic suppression.

Entities:  

Year:  2011        PMID: 21731174      PMCID: PMC3127551          DOI: 10.1016/j.jspi.2011.03.030

Source DB:  PubMed          Journal:  J Stat Plan Inference        ISSN: 0378-3758            Impact factor:   1.111


  5 in total

1.  Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?

Authors:  Andrew Hill; Diego Miralles; Tony Vangeneugden; Eric Lefebvre
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

2.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

3.  Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.

Authors:  G J Dore; D A Cooper; C Barrett; L E Goh; B Thakrar; M Atkins
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

4.  Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

Authors:  Gail V Matthews; Angeline Bartholomeusz; Stephen Locarnini; Anna Ayres; Joe Sasaduesz; Eric Seaberg; David A Cooper; Sharon Lewin; Gregory J Dore; Chloe L Thio
Journal:  AIDS       Date:  2006-04-04       Impact factor: 4.177

5.  A nonparametric likelihood test for detecting discordance between two measurements with application to censored viral load determinations.

Authors:  Zonghui Hu; Dean Follmann; Jing Qin; Robin L Dewar; Phumelele Sangweni
Journal:  Stat Med       Date:  2008-09-30       Impact factor: 2.373

  5 in total
  1 in total

1.  Landmark Estimation of Survival and Treatment Effect in a Randomized Clinical Trial.

Authors:  Layla Parast; Lu Tian; Tianxi Cai
Journal:  J Am Stat Assoc       Date:  2014-01-01       Impact factor: 5.033

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.